Keywords: Vifor Pharma, Galencia, PA21, Feseniusm Ph III, Regulatory filings
Regulatory filing preparations underway for Vifor's PA21 on good Ph III results
Article | 09 July 2012
The pivotal Phase III clinical study shows that the new phosphate binder PA21 successfully controls hyperphosphatemia in patients with chronic ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
